Stempoint Capital LP Takes $1.92 Million Position in Immunocore Holdings PLC Sponsored ADR $IMCR

Stempoint Capital LP acquired a new position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) during the 1st quarter, Holdings Channel reports. The firm acquired 63,543 shares of the company’s stock, valued at approximately $1,916,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Millennium Management LLC increased its holdings in shares of Immunocore by 334.3% during the 3rd quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock worth $45,993,000 after acquiring an additional 974,463 shares during the last quarter. Vestal Point Capital LP acquired a new stake in Immunocore during the 4th quarter valued at $20,305,000. Janus Henderson Group PLC bought a new position in Immunocore during the fourth quarter worth $15,734,000. Bellevue Group AG increased its holdings in shares of Immunocore by 14.5% in the third quarter. Bellevue Group AG now owns 2,796,803 shares of the company’s stock valued at $101,608,000 after purchasing an additional 354,973 shares during the last quarter. Finally, Tang Capital Management LLC raised its position in shares of Immunocore by 14.0% in the fourth quarter. Tang Capital Management LLC now owns 2,628,538 shares of the company’s stock valued at $91,237,000 after purchasing an additional 322,930 shares during the period. 84.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on IMCR. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Immunocore in a research note on Monday, April 20th. Zacks Research cut shares of Immunocore from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a report on Friday, July 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research report on Monday, July 13th. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $56.71.

Immunocore Trading Down 0.3%

Shares of Immunocore stock opened at $33.42 on Thursday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.15 and a current ratio of 4.18. The firm has a 50-day moving average of $31.01 and a 200-day moving average of $31.30. Immunocore Holdings PLC Sponsored ADR has a 52-week low of $27.56 and a 52-week high of $40.71. The stock has a market cap of $1.70 billion, a PE ratio of -60.76 and a beta of 0.73.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of ($0.26) by $0.51. The company had revenue of $106.68 million for the quarter, compared to analysts’ expectations of $145.20 million. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. During the same period last year, the firm earned $0.10 earnings per share. The business’s revenue for the quarter was up 13.6% on a year-over-year basis. As a group, sell-side analysts forecast that Immunocore Holdings PLC Sponsored ADR will post 0.06 EPS for the current year.

Immunocore Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.